Multiple Sclerosis Market Research
What is Multiple Sclerosis?
Multiple sclerosis (MS) is an autoimmune condition in which the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between the brain and the rest of the body. Patients can experience different symptoms of MS, including vision problems, pain, fatigue, and impaired coordination. While there is no cure for the disease, more than 20 disease-modifying therapies (DMTs) are available to help alter the course of MS.
There are four main MS subtypes:
Clinically isolated syndrome (CIS) is the first episode of neurologic symptoms caused by inflammation and demyelination in the CNS. Episodes must last at least 24 hours to be defined as CIS, although not all people with CIS symptoms develop MS.
Relapsing-remitting MS (RRMS) is the most common subtype of MS (about 85% of people at onset). Exacerbations of symptoms (relapses) are followed by recovery (remissions) and periods of stability.
Secondary progressive MS (SPMS) occurs when there is a gradual accumulation of disability unrelated to relapses, which become less frequent or stop completely (about two-thirds of people with RRMS progress to SPMS).
Primary progressive MS (PPMS) is a steady progression and worsening of the disease from the onset, without remissions. It occurs in about 10-15% of people with MS.
Spherix Global Insights – Neurology – Multiple Sclerosis Market Research
Spherix’s studies publishing this year covering Alopecia Areata include:
- RealTime Dynamix™: Multiple Sclerosis (US)
- RealTime Dynamix™: Multiple Sclerosis (Canada)
- Launch Dynamix™: SC Ocrelizumab (Genentech) in Multiple Sclerosis*
Spherix’s RealTime Dynamix™ service includes US quarterly deep dive reports and a Canadian semiannual report. Core content is supplemented with new variables each wave to provide both tracking of KPIs and an infusion of fresh market-driven insights.
Spherix’s Launch Dynamix™ service consists of two parts: monthly KPI tracking and quarterly deep dives. Monthly KPIs provide benchmarking of newly launched products for the first eighteen months of commercial availability, and quarterly deep dive reports includes promotional activity, barriers to uptake, and patient types gravitating to the launch brand.
Follow us for neurology industry news, insights & analysis:
https://www.linkedin.com/company/spherix-global-insights/
For Guests & Current Clients
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here:
